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ABSTRACT 17 
 18 
Anthocyanins are reported to have vascular bioactivity, however their mechanisms of action are 19 
largely unknown. Evidence suggests that anthocyanins modulate endothelial function, potentially by 20 
increasing nitric oxide (NO) synthesis, or enhancing NO bioavailability. This study compared the 21 
activity of cyanidin-3-glucoside, its degradation product protocatechuic acid and phase II 22 
metabolite, vanillic acid. Production of NO and superoxide, and expression of endothelial NO 23 
synthase (eNOS), NADPH oxidase (NOX) and haem oxygenase-1 (HO-1), was established in 24 
human vascular cell models. Nitric oxide levels were not modulated by the treatments, although 25 
eNOS was upregulated by cyanidin-3-glucoside, and superoxide production was decreased by both 26 
phenolic acids. Vanillic acid upregulated p22phox mRNA but did not alter NOX protein expression, 27 
although trends were observed for p47phox downregulation and HO-1 upregulation. Anthocyanin 28 
metabolites may therefore modulate vascular reactivity by inducing HO-1 and modulating NOX 29 
activity, resulting in reduced superoxide production and improved NO bioavailability. 30 
 31 
 32 
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INTRODUCTION 38 
 39 
Epidemiological evidence suggests that higher consumption of anthocyanins, a sub-class of the 40 
flavonoid family of polyphenols 1, is inversely associated with risk of hypertension 2 and 41 
cardiovascular disease mortality 3, 4. In recent randomised controlled trials, 12-week consumption of 42 
anthocyanins (320 mg/day) was associated with enhanced endothelial function in 43 
hypercholesterolaemic individuals 5, while acute consumption (724 mg) elicited a dose-dependent 44 
(biphasic) increase in endothelial-dependent vasodilation 6. Mechanistic studies suggest that 45 
anthocyanins may act to enhance vascular function through modulating levels of nitric oxide (NO) 7, 46 
8
. The reduced bioavailability of endothelial-derived NO is critical in the development of 47 
atherosclerosis 9; and a loss of NO in vascular pathologies is mediated by reaction with superoxide 48 
anion (O2.-) 10, 11 generated by vascular NADPH oxidase (NOX) enzymes 9, 12 which constitute a major 49 
source of reactive oxygen species in the vasculature. Anthocyanins have been reported to elevate the 50 
expression of the cytoprotective enzyme haem oxygenase-1 (HO-1) in human vascular endothelial 51 
cells 13 and upregulation of HO-1 with subsequent inhibition of NOX activity has been described in 52 
cell culture 14 and animal models 15. Therefore, anthocyanins could potentially improve endothelial 53 
function, by increasing the bioavailability of endothelial-derived NO and thus improving vascular 54 
homeostasis, by decreasing endothelial NOX activity and O2.- levels as a result of HO-1 induction. 55 
 56 
Anthocyanins are generally reported to have a low relative bioavailability 16, 17, suggesting their 57 
bioactivity is mediated by their metabolites, which exist in the systemic circulation at much higher 58 
concentrations 17, 18 than their precursor structures. However, most previous studies have explored the 59 
activity of anthocyanins in vitro as unmetabolised precursor structures, whilst very few have 60 
examined the activity of their phenolic metabolites. The aim of the present study was therefore to 61 
compare the bioactivity of a parent anthocyanin with its physiologically relevant phenolic acid 62 
derivatives, to establish if anthocyanin metabolites share a common or have a differential biological 63 
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activity to their unmetabolised structures. Cyanidin-3-glucoside (Figure 1A) was chosen for this study 64 
as Czank et al (2013) have recently reported the systemic concentrations of its metabolites in humans 65 
using an isotope tracer study design 17, 19. Of the 24 isotope-labelled metabolites identified, the 66 
phenolic acid degradation product protocatechuic acid (Figure 1B), and its mono-O-methylated 67 
metabolite vanillic acid (Figure 1C), were selected for comparison with the parent anthocyanin, as 68 
they share structural similarities with the known vasoactive compound apocynin 2. 69 
 70 
Bioactivity was assessed by screening physiologically relevant concentrations of the treatments (at 71 
0.1, 1, 10 µM 17) for effects on eNOS expression and activity, and angiotensin II-stimulated 72 
superoxide production, in human umbilical vein endothelial cells (HUVEC). Vanillic acid was 73 
ultimately selected to explore mechanisms potentially underlying the observed activity, by examining 74 
the modulation of NOX isoforms (and subunits) and HO-1, using both HUVEC and human coronary 75 
artery endothelial cells (HCAEC). 76 
 77 
MATERIALS AND METHODS 78 
 79 
Standards and reagents. Cyanidin-3-glucoside was purchased from Extrasynthese (Genay Cedex, 80 
France); VAS2870 from Enzo Life Sciences (Exeter, U.K.); and all other reagents were from 81 
Sigma-Aldrich (Poole, U.K.) unless otherwise noted. Stock solutions were prepared in dimethyl 82 
sulphoxide (DMSO) and stored at -80°C. Foetal bovine serum (FBS, heat-inactivated) was 83 
purchased from Biosera (Ringmer, UK) and tumour necrosis factor-alpha (TNF-α), TRIzol® 84 
reagent, and SuperScript® II Reverse Transcriptase were obtained from Life Technologies (Paisley, 85 
UK). 86 
 87 
Precision 2x real-time PCR MasterMix with SYBR®Green was obtained from PrimerDesign Ltd 88 
(Southampton, UK). Custom primer sets for human NOX2, NOX4, p22phox, p47phox and p67phox 89 
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were supplied by PrimerDesign Ltd, and custom primers for human HO-1 (HMOX-1) by Life 90 
Technologies. Primer sequences are provided as Supporting Information (Table S1). 91 
 92 
NuPAGE sample reducing agent and LDS sample buffer were purchased from Life Technologies, 93 
and Precision Plus Protein Dual Colour standards from Bio-Rad Laboratories, Inc (Hemel 94 
Hempstead, UK). 95 
 96 
Cell culture. Early passage, pooled HUVEC were purchased from TCS Cellworks (Buckingham, 97 
UK) and used between passages 2 to 4. Cells were routinely cultured in large vessel endothelial cell 98 
growth medium (TCS CellWorks) at 37°C and 5% CO2. HUVEC were sub-cultured using 0.025% 99 
trypsin and 0.01% ethylenediaminetetraacetic acid (EDTA) (TCS CellWorks). 100 
 101 
Cryo-preserved, second passage, single donor HCAEC were purchased from PromoCell GmbH 102 
(Heidelberg, Germany) and used between passages 3 to 6. Cells were routinely cultured in 103 
endothelial cell medium MV (PromoCell GmbH) at 37°C and 5% CO2. HCAEC were sub-cultured 104 
using 0.04% trypsin and 0.03% EDTA (PromoCell GmbH). 105 
 106 
Cytotoxicity assay. The maximal level of flavonoids and flavonoid metabolites reported in the 107 
systemic circulation is generally below 10 µM 1, hence this concentration was the maximum in vitro 108 
concentration utilised in the present study. Cell viability following exposure to 10 µM of treatment 109 
compounds was determined using cell proliferation reagent WST-1 (Roche Applied Science, 110 
Burgess Hill, U.K.) in accordance with the manufacturer’s protocol. The assay was conducted using 111 
fibronectin-coated microplates seeded with HUVECs at a density of ~10,000 cells/well, and 112 
subsequently grown to confluence as determined by light microscopy. After incubation with 113 
treatment compounds for 24 h, 10 µl WST-1 reagent was added to each well, and plates were 114 
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incubated for a further 4 h. Absorbance was measured at 440 - 450 nm using a microplate reader 115 
[Fluostar/Polarstar Optima, BMG Labtech (Aylesbury, U.K.)]. 116 
 117 
Nitrite/nitrate assay and eNOS enzyme-linked immunosorbent assay (ELISA). Fibronectin-118 
coated 24-well plates were seeded with HUVECs at a density of ~30,000 cells/well, and cells grown 119 
to confluence. Cells were then cultured in the absence or presence of treatment compounds (0.1, 1, 120 
or 10 µM) for 24 h; after which supernatants were removed and stored at -80°C. Cells were washed 121 
once with warm phosphate-buffered saline (PBS), and then harvested in trypsin/EDTA and trypsin-122 
blocking solution. Cell suspensions were stored at -80°C until lysis. Nitric oxide production was 123 
assessed using a colourimetric microplate assay (Cayman Chemical Company Nitrate/Nitrite 124 
Colourimetric Assay Kit from Cambridge Bioscience, Cambridge, U.K.) according to the 125 
manufacturer’s instructions. The average intra-assay coefficient of variation (CV) was 6.63% ± 126 
1.10% (mean ± SD, n=3) and the inter-assay CV was 2.38% (n=3). Quantification of eNOS in 127 
HUVEC lysates was performed with the Quantikine Human eNOS Immunoassay (R&D Systems, 128 
Abingdon, U.K.) according to the manufacturer’s instructions. The average intra-assay CV was 129 
4.67% ± 1.86% (mean ± SD, n=3) and the inter-assay CV was 6.10% (n=3). 130 
 131 
Stimulated superoxide production assay. Superoxide production was assessed using a modified 132 
cytochrome c assay 20, 21. The modified assay utilised fibronectin-coated 24-well plates seeded with 133 
HUVECs at a density of ~50,000 cells/well, and grown to confluence; after which cells were 134 
washed once with warm Medium 199 (supplemented with 2% FBS) and incubated for 16-18 h. 135 
Cells were then washed once with warm PBS, and incubated for 6 h in supplemented phenol-red 136 
free Medium 199 (Invitrogen, Paisley, U.K.) with 0.1 µM angiotensin II, 30 µM ferricytochrome c, 137 
and 0.1, 1 or 10 µM of the treatment compounds or 5 µM VAS2870 (selective NOX inhibitor 22); in 138 
the presence or absence of 65 units superoxide dismutase (SOD). Aliquots of cell supernatants were 139 
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subsequently transferred to a 96-well microplate for measurement of absorbance at 550 nm. Culture 140 
plates were frozen at -80°C for protein extraction. 141 
 142 
Direct cytochrome c reduction. Direct reduction of cytochrome c was assessed by co-incubation 143 
of treatment compounds in cell-free extracts at concentrations of 2, 20, 200 and 2000 µM with 20 144 
µM cytochrome c in PBS at 37 °C, as described previously for catechols and quinols 23. The 145 
spontaneous reduction of cytochrome c was monitored kinetically at 550 nm over 2 h. Cytochrome 146 
c reduction was quantified using the millimolar extinction coefficient for reduced cytochrome c 147 
(29.5 mM.cm-1). 148 
 149 
Superoxide production. Cell-free superoxide production by xanthine/xanthine oxidase was 150 
measured using a previously described method 21. Briefly, 200 µM of cytochrome c, 0.1 U/ml 151 
xanthine oxidase and 200 µM xanthine was added to 1, 10, 100 and 1000 µM of the treatment 152 
compounds in 50 mM sodium phosphate buffer (pH 7.4). The reaction kinetics of cytochrome c was 153 
monitored at 550 nm at 25°C over 15 min (to reaction plateau). Superoxide generated was 154 
determined by subtracting the rate of cytochrome c reduction (increase in absorbance at 550 nm) in 155 
the presence of SOD versus parallel incubations in the absence of SOD. 156 
 157 
Stimulated NOX isoform/subunit gene expression assay. Twenty-four well plates (SPL Life 158 
Sciences) coated with fibronectin were seeded with HUVEC at a density of ~30,000 cells/well, and 159 
the cells grown to confluence. Culture medium was then aspirated, and the cells were incubated for 160 
16 - 18 h in M199 supplemented with 2% FBS. Thereafter, the cells were incubated for 4 h in 161 
supplemented M199 alone (basal), or media with 0.1 µM angiotensin II in the presence or absence 162 
of 0.1, 1 or 10 µM vanillic acid. After incubation, the plates were either frozen at -80°C or used for 163 
RNA extraction. 164 
 165 
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Stimulated p47phox protein expression assay. Six-well plates (SPL Life Sciences) coated with 166 
fibronectin were seeded with HUVEC or HCAEC at a density of 100,000 cells/well, and cells were 167 
grown to confluence. Culture medium was then aspirated, and the cells were incubated for 16 - 18 h 168 
in M199 supplemented with 2% FBS (HUVEC only). Cells were subsequently incubated for 5 h in 169 
supplemented M199 alone (basal), or media with 20 ng/ml TNF-α in the presence or absence of 0.1, 170 
1, or 10 µM vanillic acid. After incubation, media was aspirated from all wells, and the plates 171 
frozen at -80°C until protein extraction. 172 
 173 
Endothelial HO-1 expression assay. Expression of HO-1 mRNA/protein was assessed using 174 
fibronectin-coated 6-well plates (SPL Life Sciences) seeded with HUVEC or HCAEC at a density 175 
of ~100,000 cells/well, and grown to ~70% confluence. Culture medium was then aspirated, and the 176 
cells were incubated for 6 h in supplemented culture medium alone (basal), or media with 10 ng/ml 177 
phorbol 12-myristate 13-acetate (PMA, positive control), vehicle control (0.005% DMSO; HUVEC 178 
only), or 0.1, 1 or 10 µM vanillic acid. After incubation, media was aspirated from all wells and the 179 
plates either frozen at -80°C, or used for RNA or protein extraction. 180 
 181 
Reverse transcription – quantitative polymerase chain reaction. RNA was extracted from cells 182 
using TRIzol® reagent, according to the manufacturer’s instructions; and 1 µg of each sample 183 
utilised in a reverse transcription reaction with SuperScript® II. Analysis of gene expression was 184 
performed using the Applied Biosystems 7500 Real time PCR System (Life Technologies; 7500 185 
software version 2.0) with SYBR®Green detection. Typically, 25 ng of cDNA was amplified with 186 
300 nM of the appropriate primer set. Following enzyme activation at 95°C for 10 minutes, 50 187 
cycles of denaturation (15 seconds at 95°C) and data collection (60 seconds at 60°C) were 188 
performed. Relative changes in gene expression  were quantified using the comparative Ct method 189 
24
. Optimal stably expressed human reference genes for normalisation of Ct data were identified 190 
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using a geNormPLUS kit with primer sets for six genes (PPIA, PRDM4, UBE2D2, UBE4A, 191 
TWY1, VIPAS39) supplied by PrimerDesign Ltd. 192 
 193 
Immunoblot analysis of endothelial NOX isoform/subunit and HO-1 expression. Cells were 194 
harvested and lysed 1% IGEPAL® (octylphenoxy polyethoxyethanol, CA-630), 150 mM NaCl, 20 195 
mM Tris and 10% glycerol (pH 8.0), supplemented with protease inhibitors (Roche Complete 196 
Protease Inhibitor Cocktail). Plates were incubated with lysis buffer for 0.5 h at 4°C, and recovered 197 
solutions subject to cell disruption by oscillation (50 Hz for 5 minutes with Qiagen TissueLyser 198 
LT). After centrifugation at 13,000 rpm (15 minutes at 4°C) the protein content of the supernatants 199 
was assayed using the Pierce BCA Protein Assay Kit (Fisher Scientific U.K. Ltd, Loughborough, 200 
U.K.) according to manufacturer’s instructions. 201 
 202 
For SDS-PAGE, cell lysates were reduced using 50 mM dithiothreitol. Briefly, 15 - 25 µg of protein 203 
was loaded onto a 4% polyacrylamide stacking gel, and separated across a 10% resolving gel (at 25 204 
mA for 1 h) prior to semi-dry transfer to Immobilon-FL PVDF membrane (Millipore, Watford, UK) 205 
at 200 mA for 1.5 h. Membranes were blocked for 1 h at room temperature and incubated overnight 206 
(at 4°C) with chicken polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 207 
Millipore) or goat polyclonal anti-actin (Santa Cruz Biotechnology, Inc., California, U.S.); and 208 
either rabbit polyclonal anti-gp91phox (Millipore), rabbit polyclonal anti-NOX4 (Abcam, 209 
Cambridge, U.K.), rabbit polyclonal anti-p47phox (Santa Cruz Biotechnology, Inc. or Abcam), or 210 
rabbit polyclonal anti-HO-1 (Abcam). Membranes were then washed prior to incubation with either 211 
donkey anti-chicken IgG (IR dye 680 LT) or donkey anti-goat IgG (IR dye 680) and goat anti-rabbit 212 
IgG (IR dye 800 CW) (Li-Cor, Cambridge, U.K.) for 1 h at room temperature. Membranes were 213 
washed and subsequently imaged and quantified using an Odyssey Infrared Imaging System (Li-214 
Cor; Application Software version 3.0.21). 215 
 216 
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Statistical analysis. Analysis of variance (ANOVA) with LSD post-hoc test was performed using 217 
SPSS software (IBM, New York, USA) version 18 for Windows. Significance was determined at 218 
the 5% level relative to basal or the assay control. Three biological replicates for each control or 219 
treatment were utilised for analysis unless otherwise noted. Means of biological replicates were 220 
represented graphically, with error bars denoting standard deviation from the mean. For each 221 
control or treatment in the stimulated superoxide production assay, mean absorbance ratio (550 222 
nm/620 nm) in the presence of SOD (n=3) was subtracted from individual absorbance ratio values 223 
in the absence of SOD (n=3), to correct for cytochrome c reduction owing to generated superoxide. 224 
Mean SOD-corrected absorbance ratio for each treatment was then represented graphically as 225 
percentage of that for the angiotensin II control. 226 
 227 
RESULTS 228 
 229 
Endothelial cytotoxicity. All treatments were screened for cytotoxicity at a concentration of 10 230 
µM; representing the highest concentration used in subsequent bioactivity investigations. No 231 
significant effects (p > 0.05) on endothelial cell viability were observed following a 24 h incubation 232 
of HUVECs with 10 µM of any treatment compound (data not shown). 233 
 234 
Endothelial NO production. Cyanidin-3-glucoside, and the phenolic derivatives protocatechuic 235 
acid and vanillic acid, did not significantly alter endothelial NO production as measured by levels of 236 
NO decomposition products (nitrite & nitrate) in HUVEC supernatants (Supporting Information, 237 
Figure S1). Resveratrol (100 µM) and PMA (10 nM) were used as positive controls to confirm the 238 
sensitivity of the assay, and elicited significant increases in total nitrite and nitrate (> 270% above 239 
basal levels). 240 
 241 
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eNOS expression in cultured HUVEC. Significant upregulation of eNOS (p < 0.001) was 242 
observed following 24 h incubation of HUVECs with 0.1, 1 & 10 µM cyanidin-3-glucoside (~4 - 7 243 
fold increase; Figure 2A). No significant alteration in eNOS levels was observed at any 244 
concentration of protocatechuic acid (Figure 2B) or vanillic acid (Figure 2C). 245 
 246 
Stimulated endothelial superoxide production. The generation of superoxide anion was 247 
confirmed using a previously reported NOX inhibitor VAS2870 22, in the presence and absence of 248 
angiotensin II, where co-incubation with VAS2870 significantly reduced superoxide production (p 249 
< 0.01) (Supporting Information, Figure S2). 250 
 251 
Significantly elevated superoxide levels were detected following incubation of cells with 0.1 µM 252 
and 1 µM cyanidin-3-glucoside (~3 fold increase; Figure 3A), relative to the angiotensin II-253 
stimulated control. A significant decrease in superoxide (p < 0.001) was induced by protocatechuic 254 
acid, at 10 µM (~5 fold decrease; Figure 3B), whilst vanillic acid elicited statistically significant 255 
reductions (p < 0.05) in superoxide at all concentrations examined (~2 fold decrease at 1 µM; 256 
Figure 3C). A linear dose-response relationship was not evident for any treatment. Control 257 
experiments were conducted to exclude possible confounding through direct reduction of 258 
cytochrome c, or scavenging of NOX-derived superoxide radicals, by the treatments. There was no 259 
significant impact on cytochrome c reduction (≤ 0.02 nmole.h-1) or superoxide levels (75-106% of 260 
control) during incubations with treatment compounds at concentrations up to 10 µM in cell-free 261 
systems. 262 
 263 
Stimulated endothelial gene expression of NOX isoforms and subunits. Vanillic acid was 264 
examined for effects on stimulated endothelial gene expression of the NOX2 and NOX4 isoforms, 265 
and the associated subunits p22phox, p47phox, and p67phox. Real time PCR melt curve data indicated 266 
non-specific amplification for NOX2, p47phox, and p67phox primer sets (data not shown); therefore 267 
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relative quantification of gene expression was performed for NOX4 and p22phox only. Co-incubation 268 
of HUVEC with angiotensin II and vanillic acid (0.1, 1 and 10 µM) for four hours elicited no 269 
significant differences in NOX4 mRNA compared to the angiotensin II control (p > 0.05; Figure 270 
4A). A statistically significant (p < 0.05) upregulation of p22phox mRNA levels was observed with 271 
vanillic acid at 0.1 µM and 1 µM (Figure 4B). 272 
 273 
Stimulated endothelial protein expression of NOX isoforms and subunits. The modulation of 274 
NOX2 and NOX4 isoforms by vanillic acid was further characterised at the protein level. Following 275 
angiotensin II stimulation, weak immunoreactive bands corresponding to NOX2 were visualised by 276 
immunoblotting of endothelial lysates, such that quantification of bands by densitometry was not 277 
possible (data not shown). By contrast, angiotensin II-induced upregulation of NOX4 expression 278 
was observed, although this was not significantly modulated (p > 0.05) by co-incubation of cells 279 
with angiotensin II and vanillic acid at any concentration examined (0.1-10 µM) (Figure 5). 280 
 281 
The effect of vanillic acid on stimulated protein expression of the key NOX2 subunit p47phox was 282 
also investigated as a possible mechanism of NOX inhibition. Following co-incubation of HUVEC 283 
with 20 ng/ml TNF-α and increasing concentrations of vanillic acid (0.1, 1, or 10 µM) for five 284 
hours, a trend towards decreased p47phox expression was observed relative to TNF-α alone (Figure 285 
6A), although these changes were not statistically significant (p = 0.06 at 1 µM and 10 µM vanillic 286 
acid). A confirmatory experiment was conducted using the HCAEC model, but here no effect was 287 
detected on TNF-α stimulated p47phox expression (p > 0.05; Figure 6B). 288 
 289 
Endothelial HO-1 expression. Modulation of HO-1 expression by vanillic acid was examined as a 290 
putative indirect mechanism of NOX inhibition. Incubation of HUVEC with the protein kinase C 291 
activator PMA (at 10 ng/ml) for six hours induced a significant increase in basal HO-1 mRNA 292 
levels (p < 0.001 versus vehicle control; Figure 7). Vanillic acid, at concentrations of 0.1, 1 and 10 293 
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µM, elicited a concentration-dependent elevation in endothelial HO-1 mRNA (~1.6-fold versus 294 
unstimulated cells with 10 µM vanillic acid), with a trend towards significance compared to vehicle 295 
control (p = 0.1) at 10 µM (Figure 7). Trends towards elevated expression of HO-1 protein in 296 
HUVEC were also observed following a six hour incubation with PMA (~1.9-fold increase versus 297 
unstimulated cells) or vanillic acid (~1.8-fold increase at 1 µM vanillic acid) relative to the vehicle 298 
control (p = 0.07 and p = 0.1 respectively; Figure 8A). Since the vehicle control (0.005% DMSO) 299 
also appeared to upregulate HO-1 protein, vanillic acid was prepared directly in aqueous solution 300 
for use in the HCAEC model, to exclude any vehicle-related effects. Expression of HO-1 protein 301 
was slightly elevated following a 6 hour incubation with PMA in the HCAEC model (~1.2-fold 302 
increase versus unstimulated cells; Figure 8B). An apparent upregulation of HO-1 protein was 303 
observed at all concentrations of vanillic acid tested (Figure 8B), with a trend towards significance 304 
at 1 µM (~1.8-fold increase; p = 0.07) relative to basal. 305 
 306 
DISCUSSION 307 
 308 
The low bioavailability of parent anthocyanins suggests their bioactivity in vivo is mediated by 309 
phenolic metabolites, which have recently been reported as the main circulating species following 310 
anthocyanin consumption 17-19. Here, we report that phenolic metabolites appear to modulate 311 
vascular endothelial cell function through alternative mechanisms to those previously described for 312 
parent anthocyanins. In the present study, the parent anthocyanin increased eNOS expression, 313 
whereas phenolic derivatives had no effect. However, these metabolites elicited reductions in 314 
superoxide production, which could subsequently decrease scavenging of NO. Recent studies by 315 
Czank et al (2013) and de Ferrars et al (2014) have confirmed a physiologically appropriate range 316 
for anthocyanin metabolites in humans of 0.1 - 10 µM 17-19 and the present study assessed potential 317 
mechanisms of activity at these concentrations. Indeed, following consumption of 500 mg 13C-318 
labelled cyanidin-3-glucoside, a serum Cmax of 1.85 µM has been reported for vanillic acid, with 1 319 
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µM concentrations persisting for up to 24 hours 19; suggesting phenolic derivatives of anthocyanins 320 
may be present in the systemic circulation at low micromolar levels for at least 18-24 hours after 321 
ingestion of parent anthocyanins. Based on our findings, physiologically relevant levels of 322 
anthocyanin metabolites are likely to act indirectly to maintain vascular homeostasis, through 323 
induction of HO-1 and decreased endothelial superoxide generation, as opposed to directly 324 
stimulating eNOS activity and NO production. 325 
 326 
Endothelium-derived nitric oxide is a key component of vascular homeostasis 11 and prior in vitro 327 
studies have described both upregulation and activation of the eNOS enzyme by anthocyanins 328 
(including cyanidin-3-glucoside) in cultured endothelial cells at concentrations ranging from 0.001 329 
µM up to 250 µM 7, 8, 13. Interestingly, in the present study we observed differential bioactivity for 330 
cyanidin-3-glucoside relative to its phenolic acid derivatives. Specifically, no treatment compounds 331 
significantly modulated endothelial NO production, however, cyanidin-3-glucoside significantly 332 
upregulated eNOS protein levels, while the phenolic derivatives remained inactive (Figure 2). 333 
 334 
NOX enzymes represent a major source of reactive oxygen species in the vasculature 12, 25 and 335 
anthocyanin metabolites could act as endothelial NOX inhibitors, based on previously reported 336 
structure-activity studies 21. In the current study, differential bioactivity was again observed for 337 
cyanidin-3-glucoside relative to its phenolic acid derivatives. A significant elevation in superoxide 338 
levels was elicited by cyanidin-3-glucoside; and in contrast, both protocatechuic acid and vanillic 339 
acid significantly reduced superoxide levels (Figure 3). Whilst previous reports have described 340 
superoxide scavenging 26 and direct cytochrome c reduction 27 elicited by flavonoids, such activity 341 
is reported at much higher concentrations (~40 - 100 µM) than those used in the current 342 
investigation (≤ 10µM), and control experiments in cell-free incubations confirmed negligible 343 
superoxide scavenging or direct cytochrome c reduction by the treatments. High concentrations of 344 
phenolic compounds in culture medium have also been reported to result in the generation of 345 
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hydrogen peroxide 28, which could potentially interfere with assay methodologies; however, only 346 
minimal hydrogen peroxide formation has previously been reported for delphinidin (at 10 µM) 28 347 
which is one of the most reactive anthocyanins 29. Therefore, data from cell-free experiments in the 348 
current study indicate that the treatment compounds do not directly scavenge superoxide radicals, as 349 
negligible activity was observed, and the present findings likely reflect reduced endothelial 350 
superoxide generation as opposed to radical scavenging. 351 
 352 
The phenolic derivative vanillic acid (the methylated metabolite of protocatechuic acid) was 353 
subsequently selected to explore mechanisms potentially underlying the observed reductions in 354 
superoxide production. In the present study, vanillic acid at a concentration of 1 µM significantly 355 
reduced endothelial superoxide levels, which is comparable to the Cmax value reported by Czank et 356 
al (2013) for 13C-labelled phase II conjugates of protocatechuic acid (2.35 µM) following ingestion 357 
of 13C-labelled cyanidin-3-glucoside 17. Steffen et al (2008) have previously described NOX 358 
inhibitory activity of vanillic acid in disintegrated HUVEC (IC50 = 8.1 µM), with minimal direct 359 
superoxide scavenging activity in a cell-free system (IC50 > 100 µM) 21; which was confirmed by 360 
the absence of direct superoxide scavenging by vanillic acid in the present study. 361 
 362 
NOX4 is reported to be the major vascular endothelial isoform 30, 31, producing mainly hydrogen 363 
peroxide 32; and whilst NOX4-derived hydrogen peroxide would not act to limit NO bioavailability 364 
33
, it might induce vasodilation through hyperpolarisation independently of NO activity 34. In 365 
contrast NOX2 generates superoxide 35 and may have a key role in regulating vascular function 32, 366 
36
. Both NOX2 and NOX4 associate with the integral membrane protein p22phox 37, but activation of 367 
NOX2 follows the recruitment of additional cytosolic proteins including p47phox (‘organiser’ 368 
subunit) and p67phox (‘activator’ subunit) 37, 38. Modulation of the expression of NOX2 and NOX4 369 
isoforms, and associated subunits (p22phox, p47phox, and p67phox) by vanillic acid was therefore 370 
explored using RT-qPCR. Co-incubation of angiotensin II with vanillic acid elicited no significant 371 
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changes in levels of endothelial NOX4 mRNA relative to angiotensin II alone (Figure 4A). 372 
However, a significant upregulation of p22phox mRNA levels was observed with 0.1 and 1 µM 373 
vanillic acid (Figure 4B), whilst we were unable to assess transcriptional modulation of the 374 
superoxide-generating NOX2 isoform, or p47phox and p67phox. Therefore the effects of vanillic acid 375 
on the stimulated expression of NOX2 and p47phox, and also NOX4, were explored at the protein 376 
level. 377 
 378 
There was no significant modulation of stimulated NOX4 protein expression by vanillic acid 379 
(Figure 5), indicating that this particular metabolite does not affect endothelial NOX4 protein. 380 
NOX2 expression was more difficult to discern by immunoblotting of cell lysates, which may 381 
reflect low mRNA/protein expression in vascular cells, and/or poor antibody specificity; although 382 
upregulation of NOX2 in HUVECs following angiotensin II stimulation has been previously 383 
reported 20. Interestingly, the observed elevation in p22phox mRNA induced by vanillic acid did not 384 
appear to be associated with increased NOX4 or NOX2 protein levels. Modulation of p47phox 385 
protein expression was examined as a possible mechanism of NOX2 inhibition, and here a trend 386 
was observed towards downregulation of p47phox protein following co-incubation with TNF-α and 387 
vanillic acid (Figure 6A). Interestingly, in the HCAEC model, vanillic acid did not modulate 388 
stimulated p47phox expression (Figure 6B), and thus vanillic acid does not appear to significantly 389 
alter p47phox levels (under the present conditions) and therefore affect NOX2 activity by this 390 
mechanism. However, the anthocyanidin delphinidin has recently been reported to inhibit p47phox 391 
translocation and NOX activity in human dermal fibroblasts 39, suggesting another potential 392 
mechanism by which anthocyanins and/or their degradation products could modulate NOX 393 
function. 394 
 395 
Upregulation of HO-1 has been reported to inhibit NOX function 14, 15; and previous studies have 396 
described induction of HO-1 expression by anthocyanins and/or their metabolites in human 397 
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endothelial cells 13, 40. For example, Nrf2 nuclear translocation and HO-1 expression in cultured 398 
HUVEC was elicited by serum samples obtained from healthy subjects following ingestion of 160 399 
mg purified anthocyanins, which may reflect activity of anthocyanin metabolites as opposed to 400 
parent compounds 40. Moreover, delphindin-3-glucoside has previously been reported to enhance 401 
survival of murine hepatocytes exposed to a cytotoxic concentration of epigallocatechin-3-gallate 402 
through upregulation of HO-1 mRNA levels 41. Endothelial homeostasis is maintained through the 403 
action of vasodilators such as NO, however NO bioactivity is diminished by radicals such as O2.- 404 
which are produced through activation of NOX 9, 12. Anthocyanin metabolites could potentially 405 
indirectly maintain vascular homeostasis by inducing HO-1, with subsequent inhibition of NOX 406 
activity, thus reducing the scavenging of NO by NOX-derived superoxide 14, 15, 40. Therefore the 407 
potential indirect effect of vanillic acid on NOX activity was explored by assessing modulation of 408 
endothelial HO-1 expression. Following exposure of HUVEC to vanillic acid, elevated HO-1 409 
mRNA levels were observed in what appeared to be a concentration-dependent response (Figure 7), 410 
with a trend towards significance relative to the vehicle control (at 10 µM vanillic acid). Likewise, 411 
vanillic acid increased HUVEC HO-1 protein expression (Figure 8A), and densitometric analysis 412 
indicated a trend towards significance at 1 µM. The vehicle control also appeared to moderately 413 
upregulate HO-1, reflecting previously reported studies in HUVEC with low concentrations of 414 
DMSO (0 - 0.8%) 42. As such, vanillic acid was prepared directly in aqueous solution for 415 
investigation in the HCAEC model; where a similar trend for upregulation of HO-1 protein was 416 
evident (at 1 µM; Figure 8B), suggesting an inverted U-shaped dose-response. 417 
 418 
A possible limitation of the current investigation was the use of HUVEC as an in vitro model. 419 
Whilst HUVEC are widely used for research concerning general properties of endothelial cells 43, 420 
an arterial endothelial cell type may be more appropriate for studies investigating the potential 421 
modulation of NOX activity in relation to endothelial dysfunction. Thus as part of the current 422 
investigation confirmatory studies were conducted for potential modulation of p47phox/HO-1 423 
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expression, using HCAEC as a more physiologically representative endothelial model. Furthermore, 424 
in the present study there was no effect of cyanidin-3-glucoside on endothelial NO production 425 
(Supporting Information, Figure S1), despite a previous report of activation of eNOS by cyanidin-3-426 
glucoside at concentrations of ≤5 µM in HUVECs 7. It is possible that assessing eNOS activity by 427 
investigating enzyme phosphorylation, as described previously for blackcurrant anthocyanins in a 428 
HUVEC model 44, could have provided further information as to the effects of treatment 429 
compounds upon eNOS. NO production was clearly increased by PMA and resveratrol in control 430 
experiments, indicating adequate assay sensitivity for the detection of NO-derived nitrite/nitrate in 431 
aqueous solution. It is however possible that the assay was not sensitive enough to detect subtle 432 
changes in nitrite/nitrate. Interestingly, and with the possible exception of the upregulation of eNOS 433 
by cyanidin-3-glucoside, linear dose-response relationships were not observed for any treatment in 434 
the current investigation, suggesting differential bioactivity of anthocyanins and their metabolites 435 
across dose ranges, as described previously for cyanidin-3-glucoside 8. However, as only three 436 
concentrations of the treatment compounds were assessed in the current study, it is not possible to 437 
draw definitive conclusions regarding dose-response relationships, and a wider dosage range is 438 
required to confirm our observations. 439 
 440 
Another limitation of the present study was the poor qPCR specificity observed for NOX2, p47phox 441 
and p67phox, which precluded determination of relative changes in expression for these transcripts. 442 
Previously reported studies have suggested low or no endothelial expression of NOX2 mRNA 30, 45, 443 
and low expression of p47phox and p67phox mRNA in HUVEC 30. Moreover, minimal changes were 444 
detected in NOX4 gene expression, and p47phox protein expression, following stimulation with 445 
angiotensin II or TNF-α respectively; although limited upregulation of p47phox was consistent in 446 
both HUVEC and HCAEC models. 447 
 448 
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In the present study, cyanidin-3-glucoside significantly upregulated endothelial expression of eNOS 449 
as previously reported for unmetabolised anthocyanins 8, 13, however the phenolic acid derivatives 450 
were not active. By contrast, both the degradation product protocatechuic acid, and its phase II 451 
metabolite vanillic acid, significantly reduced endothelial superoxide levels; whereas the parent 452 
anthocyanin did not. These data suggest a differential bioactivity of anthocyanins relative to their 453 
phenolic derivatives. Our findings therefore indicate that anthocyanins may directly stimulate 454 
eNOS, eliciting improved endothelial function; however, when anthocyanins are metabolized, this 455 
direct effect upon eNOS is lost. Nevertheless, their metabolites could maintain vascular homeostasis 456 
through indirectly preserving NO bioactivity, by mechanisms involving NOX or HO-1. It must be 457 
noted that Czank et al (2013) identified 16 phenolic metabolites of cyanidin-3-glucoside in human 458 
serum 17, which should all be investigated for potential vascular bioactivity in future studies. 459 
Indeed, preliminary data from ongoing studies in our laboratory suggest PCA, and PCA in 460 
combination with VA, upregulate HO-1 protein expression in rat aortic smooth muscle cells in vitro 461 
(data not shown). 462 
 463 
In conclusion, there was no direct effect of vanillic acid on endothelial protein expression of eNOS 464 
or NOX isoforms in the present investigation, whereas HO-1 protein was modestly increased; 465 
indicating different mechanisms of bioactivity for phenolic derivatives relative to parent 466 
anthocyanins. This also suggests a potential indirect activity of anthocyanin metabolites in 467 
maintaining vascular homeostasis in vivo.  468 
 469 
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ABBREVIATIONS USED 470 
 471 
Ang II, angiotensin II; ANOVA, analysis of variance; CV, coefficient of variation; DMSO, 472 
dimethyl sulphoxide; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked 473 
immunosorbent assay; eNOS, endothelial nitric oxide synthase; FBS; foetal bovine serum; GAPDH, 474 
glyceraldehyde-3-phosphate dehydrogenase; HCAEC, human coronary artery endothelial cell; HO-475 
1, haem oxygenase-1; HUVEC, human umbilical vein endothelial cell; NADPH, reduced 476 
nicotinamide adenine dinucleotide phosphate; NO, nitric oxide; NOX, NADPH oxidase; O2.-, 477 
superoxide; PBS, phosphate-buffered saline; PMA, phorbol 12-myristate 13-acetate; SOD, 478 
superoxide dismutase; TNF-α, tumour necrosis factor-alpha; VA, vanillic acid. 479 
 480 
ACKNOWLEDGEMENTS 481 
 482 
This study was supported by a two UK Biotechnology and Biological Sciences Research Council 483 
(BBSRC) CASE studentships (M. Edwards & Gary Woodward) in partnership with 484 
GlaxoSmithKline (UK).The authors would like to thank Ilde Rodriguez-Ramiro and Emily Warner 485 
(Department of Nutrition, Norwich Medical School, University of East Anglia) for their work on 486 
the bioactivity of flavonoids and phenolic metabolites in rat aortic smooth muscle cells (supported 487 
by the BBSRC Diet and Health Research Industry Club; BB/H004963/1, BB/I006028/1,).  488 
The authors have declared no conflict of interest. 489 
 490 
SUPPORTING INFORMATION DESCRIPTION 491 
 492 
Primer sequences for custom primer sets (human HMOX-1, NOX2, NOX4, p22phox, p47phox and 493 
p67phox) are provided as Supporting Information. 494 
 495 
Page 21 of 37 
REFERENCES 496 
 497 
1. Crozier A., Jaganath I. B.; Clifford M. N. Dietary phenolics: chemistry, bioavailability and 498 
effects on health. Nat. Prod. Rep. 2009, 26, 1001-43. 499 
2. Cassidy A., O'Reilly E. J., Kay C., Sampson L., Franz M., Forman J., Curhan G.; Rimm E. B. 500 
Habitual intake of flavonoid subclasses and incident hypertension in adults. Am. J Clin. Nutr. 2010, 501 
93, 338-47. 502 
3. Mink P. J., Scrafford C. G., Barraj L. M., Harnack L., Hong C. P., Nettleton J. A.; Jacobs D. R., 503 
Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal 504 
women. Am. J Clin. Nutr. 2007, 85, 895-909. 505 
4. McCullough M. L., Peterson J. J., Patel R., Jacques P. F., Shah R.; Dwyer J. T. Flavonoid intake 506 
and cardiovascular disease mortality in a prospective cohort of US adults. Am. J Clin. Nutr. 2012, 507 
95, 454-64. 508 
5. Zhu Y., Xia M., Yang Y., Liu F., Li Z., Hao Y., Mi M., Jin T.; Ling W. Purified Anthocyanin 509 
Supplementation Improves Endothelial Function via NO-cGMP Activation in Hypercholesterolemic 510 
Individuals. Clin. Chem. 2011, 57, 1524-33. 511 
6. Rodriguez-Mateos A., Rendeiro C., Bergillos-Meca T., Tabatabaee S., George T. W., Heiss C.; 512 
Spencer J. P. Intake and time dependence of blueberry flavonoid–induced improvements in vascular 513 
function: a randomized, controlled, double-blind, crossover intervention study with mechanistic 514 
insights into biological activity. Am. J Clin. Nutr. 2013, 98, 1179-91. 515 
7. Xu J. W., Ikeda K.; Yamori Y. Cyanidin-3-glucoside regulates phosphorylation of endothelial 516 
nitric oxide synthase. FEBS Lett. 2004, 574, 176-80. 517 
8. Xu J. W., Ikeda K.; Yamori Y. Upregulation of endothelial nitric oxide synthase by cyanidin-3-518 
glucoside, a typical anthocyanin pigment. Hypertension. 2004, 44, 217-22. 519 
9. Higashi Y., Noma K., Yoshizumi M.; Kihara Y. Endothelial function and oxidative stress in 520 
cardiovascular diseases. Circ. J. 2009, 73, 411-8. 521 
Page 22 of 37 
10. Wever R., Stroes E.; Rabelink T. J. Nitric oxide and hypercholesterolemia: a matter of oxidation 522 
and reduction? Atherosclerosis. 1998, 137 Suppl, S51-60. 523 
11. Naseem K. M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 2005, 26, 524 
33-65. 525 
12. Bonomini F., Tengattini S., Fabiano A., Bianchi R.; Rezzani R. Atherosclerosis and oxidative 526 
stress. Histol. Histopathol. 2008, 23, 381-90. 527 
13. Sorrenti V., Mazza F., Campisi A., Di Giacomo C., Acquaviva R., Vanella L.; Galvano F. Heme 528 
oxygenase induction by cyanidin-3-O-beta-glucoside in cultured human endothelial cells. Mol. 529 
Nutr. Food Res. 2007, 51, 580-6. 530 
14. Jiang F., Roberts S. J., Datla S.; Dusting G. J. NO modulates NADPH oxidase function via 531 
heme oxygenase-1 in human endothelial cells. Hypertension. 2006, 48, 950-7. 532 
15. Datla S. R., Dusting G. J., Mori T. A., Taylor C. J., Croft K. D.; Jiang F. Induction of Heme 533 
Oxygenase-1 In Vivo Suppresses NADPH Oxidase–Derived Oxidative Stress. Hypertension. 2007, 534 
50, 636-42. 535 
16. Vitaglione P., Donnarumma G., Napolitano A., Galvano F., Gallo A., Scalfi L.; Fogliano V. 536 
Protocatechuic acid is the major human metabolite of cyanidin-glucosides. J Nutr. 2007, 137, 2043-537 
8. 538 
17. Czank C., Cassidy A., Zhang Q., Morrison D. J., Preston T., Kroon P. A., Botting N. P.; Kay C. 539 
D. Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a 13C-tracer study. 540 
Am. J Clin. Nutr. 2013, 97, 995-1003. 541 
18. de Ferrars R. M., Cassidy A., Curtis P.; Kay C. D. Phenolic metabolites of anthocyanins 542 
following a dietary intervention study in post-menopausal women. Mol. Nutr. Food Res. 2014, 58, 543 
490-502. 544 
19. de Ferrars R. M., Czank C., Zhang Q., Botting N. P., Kroon P. A., Cassidy A.; Kay C. D. The 545 
pharmacokinetics of anthocyanins and their metabolites in humans. Br. J Pharmacol. 2014, 171, 546 
3268-82. 547 
Page 23 of 37 
20. Rueckschloss U., Quinn M. T., Holtz J.; Morawietz H. Dose-dependent regulation of NAD(P)H 548 
oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II 549 
type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 550 
2002, 22, 1845-51. 551 
21. Steffen Y., Gruber C., Schewe T.; Sies H. Mono-O-methylated flavanols and other flavonoids 552 
as inhibitors of endothelial NADPH oxidase. Arch. Biochem. Biophys. 2008, 469, 209-19. 553 
22. Stielow C., Catar R. A., Muller G., Wingler K., Scheurer P., Schmidt H. H.; Morawietz H. 554 
Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial 555 
cells. Biochem. Biophys. Res. Commun. 2006, 344, 200-5. 556 
23. Saleem M. M.; Wilson M. T. Kinetic studies on the reduction of cytochrome c. Reaction with 557 
dihydroxy conjugated compounds (catechols and quinols). Biochem J. 1982, 201, 433-44. 558 
24. Schmittgen T. D.; Livak K. J. Analyzing real-time PCR data by the comparative C(T) method. 559 
Nat. Protoc. 2008, 3, 1101-8. 560 
25. Bedard K.; Krause K. H. The NOX family of ROS-generating NADPH oxidases: physiology 561 
and pathophysiology. Physiol. Rev. 2007, 87, 245-313. 562 
26. Taubert D., Breitenbach T., Lazar A., Censarek P., Harlfinger S., Berkels R., Klaus W.; Roesen 563 
R. Reaction rate constants of superoxide scavenging by plant antioxidants. Free Rad. Biol. Med. 564 
2003, 35, 1599-607. 565 
27. Skemiene K., Rakauskaite G., Trumbeckaite S., Liobikas J., Brown G. C.; Borutaite V. 566 
Anthocyanins block ischaemia-induced apoptosis in the perfused heart and support mitochondrial 567 
respiration potentially by reducing cytosolic cytochrome c. Int. J Biochem. Cell. Biol. 2012, 45, 23-568 
9. 569 
28. Long L. H., Hoi A.; Halliwell B. Instability of, and generation of hydrogen peroxide by, 570 
phenolic compounds in cell culture media. Arch. Biochem. Biophys. 2010, 501, 162-9. 571 
29. Woodward G., Kroon P., Cassidy A.; Kay C. Anthocyanin stability and recovery: implications 572 
for the analysis of clinical and experimental samples. J Agric. Food Chem. 2009, 57, 5271-8. 573 
Page 24 of 37 
30. Ago T., Kitazono T., Ooboshi H., Iyama T., Han Y. H., Takada J., Wakisaka M., Ibayashi S., 574 
Utsumi H.; Iida M. Nox4 as the Major Catalytic Component of an Endothelial NAD(P)H Oxidase. 575 
Circulation. 2004, 109, 227-33. 576 
31. Takac I., Schroder K.; Brandes R. P. The Nox Family of NADPH Oxidases: Friend or Foe of 577 
the Vascular System? Curr. Hypertens. Rep. 2011, 14, 70-8. 578 
32. Brown D. I.; Griendling K. K. Nox proteins in signal transduction. Free Radic. Biol. Med. 2009, 579 
47, 1239-53. 580 
33. Brandes R. P., Takac I.; Schroder K. No Superoxide--No Stress?: Nox4, the Good NADPH 581 
Oxidase! Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1255-7. 582 
34. Ray R., Murdoch C. E., Wang M., Santos C. X., Zhang M., Alom-Ruiz S., Anilkumar N., 583 
Ouattara A., Cave A. C., Walker S. J., Grieve D. J., Charles R. L., Eaton P., Brewer A. C.; Shah A. 584 
M. Endothelial Nox4 NADPH Oxidase Enhances Vasodilatation and Reduces Blood Pressure In 585 
Vivo. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1368-76. 586 
35. Brandes R. P., Weissmann N.; Schroder K. NADPH oxidases in cardiovascular disease. Free 587 
Radic. Biol. Med. 2010, 49, 687-706. 588 
36. Schroder K. Isoform specific functions of Nox protein-derived reactive oxygen species in the 589 
vasculature. Curr. Opin. Pharmacol. 2010, 10, 122-6. 590 
37. Sumimoto H., Miyano K.; Takeya R. Molecular composition and regulation of the Nox family 591 
NAD(P)H oxidases. Biochem. Biophys. Res. Commun. 2005, 338, 677-86. 592 
38. Drummond G. R., Selemidis S., Griendling K. K.; Sobey C. G. Combating oxidative stress in 593 
vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011, 10, 453-71. 594 
39. Lim T.-G., Jung S. K., Kim J.-e., Kim Y., Lee H. J., Jang T. S.; Lee K. W. NADPH oxidase is a 595 
novel target of delphinidin for the inhibition of UVB-induced MMP-1 expression in human dermal 596 
fibroblasts. Exp. Dermatol. 2013, 22, 428-30. 597 
Page 25 of 37 
40. Cimino F., Speciale A., Anwar S., Canali R., Ricciardi E., Virgili F., Trombetta D.; Saija A. 598 
Anthocyanins protect human endothelial cells from mild hyperoxia damage through modulation of 599 
Nrf2 pathway. Genes Nutr. 2013, 8, 391-9. 600 
41. Inoue H., Maeda-Yamamoto M., Nesumi A.; Murakami A. Delphinidin-3-O-galactoside 601 
protects mouse hepatocytes from (-)-epigallocatechin-3-gallate-induced cytotoxicity via up-602 
regulation of heme oxygenase-1 and heat shock protein 70. Nutr. Res. 2012, 32, 357-64. 603 
42. Liang C., Xue Z., Cang J., Wang H.; Li P. Dimethyl sulfoxide induces heme oxygenase-1 604 
expression via JNKs and Nrf2 pathways in human umbilical vein endothelial cells. Mol. Cell 605 
Biochem. 2011, 355, 109-15. 606 
43. Baudin B., Bruneel A., Bosselut N.; Vaubourdolle M. A protocol for isolation and culture of 607 
human umbilical vein endothelial cells. Nat. Protoc. 2007, 2, 481-5. 608 
44. Edirisinghe I., Banaszewski K., Cappozzo J., McCarthy D.; Burton-Freeman B. M. Effect of 609 
Black Currant Anthocyanins on the Activation of Endothelial Nitric Oxide Synthase (eNOS) in 610 
Vitro in Human Endothelial Cells. J Agric. Food Chem. 2011, 59, 8616–24. 611 
45. Alvarez E., Rodino-Janeiro B. K., Ucieda-Somoza R.; Gonzalez-Juanatey J. R. Pravastatin 612 
counteracts angiotensin II-induced upregulation and activation of NADPH oxidase at plasma 613 
membrane of human endothelial cells. J Cardiovasc. Pharmacol. 2010, 55, 203-12. 614 
 615 
 616 
 Page 26 of 37 
FIGURE CAPTIONS 617 
 618 
Figure 1. Chemical structures of the anthocyanin cyanidin-3-glucoside (A), its B-ring degradation 619 
product protocatechuic acid (B), and the mono-O-methylated metabolite of protocatechuic acid, 620 
vanillic acid (C). COMT, catechol-O-methyltransferase. 621 
 622 
Figure 2. Modulation of endothelial eNOS expression (as quantified by ELISA of cell lysates) 623 
following 24 h incubation of HUVECs with vehicle control [0.05% DMSO in supplemented culture 624 
medium] (VC), or 0.1-10 µM of cyanidin-3-glucoside (A), protocatechuic acid (B), and vanillic 625 
acid (C). Data are graphed as mean eNOS protein as percentage of vehicle control (designated as 626 
100% and marked by dashed line); mean ± SD (n=3). *Significant difference versus vehicle control 627 
(p < 0.05). 628 
 629 
Figure 3. Modulation of angiotensin II (Ang II)-stimulated HUVEC endothelial superoxide 630 
production by 0.1-10 µM cyanidin-3-glucoside (A), protocatechuic acid (B), or vanillic acid (C). 631 
Superoxide production was quantified by reduction of extracellular ferricytochrome c. Data are 632 
graphed as SOD-corrected mean absorbance (OD) ratio (550 nm/620 nm) as percentage of Ang II 633 
control (designated as 100% and marked by dashed line); mean ± SD (n=3). *Significant difference 634 
versus Ang II-stimulated control (p < 0.05). 635 
 636 
Figure 4. Modulation of HUVEC NOX4 (A) or p22phox (B) mRNA levels following 4 h incubation 637 
with 0.1 µM angiotensin II control (Ang II), or Ang II with 0.1 µM, 1 µM or 10 µM vanillic acid, 638 
presented as fold change versus unstimulated cells (basal; designated as 1 and marked by dashed 639 
line). Relative quantification was performed by RT-qPCR using the comparative Ct method, 640 
incorporating the geometric mean of reference genes UBE4A and VIPAS39 as the normalisation 641 
 Page 27 of 37 
factor. Data are graphed as mean ± SD (n=3). *Significant difference versus Ang II-stimulated 642 
control (p < 0.05). 643 
 644 
Figure 5. Expression of NOX4 protein in cell lysates from unstimulated HUVECs (basal) and 645 
following 6 h incubation with 0.1 µM angiotensin II (Ang II), or Ang II with 0.1 µM, 1 µM or 10 646 
µM vanillic acid (VA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was utilised as a 647 
loading control for immunoblotting of cell lysates. Graphs show fold increase in NOX4 expression 648 
relative to basal (designated as 1 and marked by dashed line), after quantification by densitometry 649 
and normalisation to loading control (mean ± SD, n=5). 650 
 651 
Figure 6. Expression of p47phox protein in HUVEC (A) or HCAEC (B) lysates from unstimulated 652 
cells (basal) and following 5 h incubation with 20ng/ml TNF-α, or TNF-α with 0.1 µM, 1 µM or 10 653 
µM vanillic acid. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was utilised as a loading 654 
control for immunoblotting of cell lysates. Graphs show fold increase in p47phox expression relative 655 
to basal (designated as 1 and marked by dashed line), after quantification by densitometry and 656 
normalisation to loading control. Data are graphed as mean ± SD (n=5 for HUVEC and n=4 for 657 
HCAEC). 658 
 659 
Figure 7. Modulation of HUVEC HO-1 mRNA levels following 6 h incubation with vehicle control 660 
(VC, 0.005% DMSO), 10 ng/ml phorbol 12-myristate 13-acetate (PMA), or 0.1 µM, 1 µM or 10 661 
µM vanillic acid, presented as fold change versus untreated (basal) cells (designated as 1 and 662 
marked by dashed line). Relative quantification was performed by RT-qPCR using the comparative 663 
Ct method, incorporating the geometric mean of human reference genes TYW1 and PPIA as the 664 
normalisation factor. Data are graphed as mean ± SD (n=3). *Significant difference versus vehicle 665 
control (*p < 0.01). 666 
 667 
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Figure 8. Expression of HO-1 protein in HUVEC (A) or HCAEC (B) lysates from untreated cells 668 
(basal) and following 6 h incubation with 10 ng/ml phorbol 12-myristate 13-acetate (PMA), vehicle 669 
control (VC, 0.005% DMSO; HUVEC only) or 0.1 µM, 1 µM or 10 µM vanillic acid. 670 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was utilised as a loading control for 671 
immunoblotting of cell lysates. Graphs show fold increase in HO-1 expression relative to basal 672 
(designated as 1 and marked by dashed line), after quantification by densitometry and normalisation 673 
to loading control. Data are graphed as mean ± SD (n=4). 674 
 675 
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